Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher`s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Website: lixte.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -7.4% (LTM)

Entry Point: Share price is 88.4% higher than minimum and 90.0% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: LIXT
Share price, USD:  (+1.2%)3.26
year average price 3.31  


year start price 5.61 2023-04-30

max close price 7.53 2023-07-17

min close price 1.73 2024-01-18

current price 3.26 2024-04-28
Common stocks: 16 649 510

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  ---
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 54
Net Debt ($m): -4
EV (Enterprise Value): 50
Price to Book: 13.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol LIXT LIXT LIXT LIXT LIXT LIXT LIXT
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-19 2023-11-09 2023-08-09 2023-05-10 2023-03-29 2022-11-08 2022-08-10
acceptedDate 2024-03-19 08:30:54 2023-11-09 17:16:22 2023-08-09 08:30:41 2023-05-10 08:30:30 2023-03-29 08:30:42 2022-11-08 08:30:31 2022-08-10 08:30:52
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 149 071 132 487 427 457 189 085 453 620 272 388 164 810
generalAndAdministrativeExpenses 876 839 534 013 862 571 1M 1M 1M 1M
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 876 839 534 013 862 571 1M 1M 1M 1M
otherExpenses 0 0 0 0 -584 024 0 269 281
operatingExpenses 1M 132 487 2M 1M 2M 1M 2M
costAndExpenses 1M 1M 2M 1M 2M 1M 2M
interestIncome 3948.000 5809.000 2714.000 5015.000 6984.000 3911.000 191.000
interestExpense 10 145 -279.000 1948.000 3861.000 3635.000 2119.000 627.000
depreciationAndAmortization 1025.910 1024.181 2714.000 5015.000 6984.000 3911.000 0
ebitda -1M -1M -2M -1M -2M -1M -2M
ebitdaratio 0 0 0 0 0 0 0
operatingIncome -1M -1M -2M -1M -2M -1M -2M
operatingIncomeRatio 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -6345.000 5421.000 877.000 2488.000 1314.000 492.000 -294.000
incomeBeforeTax -1M -1M -2M -1M -2M -1M -2M
incomeBeforeTaxRatio 0 0 0 0 0 0 0
incomeTaxExpense -1026.910 -1024.181 -766.000 1373.000 -5210.000 -2611.000 0
netIncome -1M -1M -2M -1M -2M -1M -2M
netIncomeRatio 0 0 0 0 0 0 0
eps -0.460 -0.490 -1.000 -0.082 -0.100 -0.089 -0.100
epsdiluted -0.460 -0.490 -1.000 -0.082 -0.100 -0.089 -0.100
weightedAverageShsOut 2M 2M 2M 17M 16M 17M 16M
weightedAverageShsOutDil 2M 2M 2M 17M 16M 17M 16M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol LIXT LIXT LIXT LIXT LIXT LIXT LIXT
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-19 2023-11-09 2023-08-09 2023-05-10 2023-03-29 2022-11-08 2022-08-10
acceptedDate 2024-03-19 08:30:54 2023-11-09 17:16:22 2023-08-09 08:30:41 2023-05-10 08:30:30 2023-03-29 08:30:42 2022-11-08 08:30:31 2022-08-10 08:30:52
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 4M 5M 3M 4M 5M 7M 8M
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 4M 5M 3M 4M 5M 7M 8M
netReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
otherCurrentAssets 27 116 27 840 49 563 56 099 10 380 257 628 288 034
totalCurrentAssets 4M 5M 3M 4M 6M 7M 8M
propertyPlantEquipmentNet 0 0 0 0 0 0 0
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 78 016 78 014 78 015 0 0 0 0
totalNonCurrentAssets 78 016 78 014 78 015 0 0 0 0
otherAssets 0 -78 014 -78 015 0 0 0 0
totalAssets 4M 5M 3M 4M 6M 7M 8M
accountPayables 156 758 221 171 366 528 0 229 764 307 398 0
shortTermDebt -193.350 -221 171 -366 528 0 -394 786 0 0
taxPayables 0 0 0 0 0 0 0
deferredRevenue 157 100 90 565 36 086 26 356 165 022 100 930 158 832
otherCurrentLiabilities 193.350 221 171 366 528 223 631 394 786 0 372 708
totalCurrentLiabilities 313 858 311 736 402 614 249 987 394 786 408 328 531 540
longTermDebt 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 26 356 394 786 -408 328 0
totalNonCurrentLiabilities 0 0 0 26 356 394 786 408 328 0
otherLiabilities 0 0 0 -26 356 -394 786 -408 328 0
capitalLeaseObligations 0 0 0 0 0 0 0
totalLiabilities 313 858 311 736 402 614 249 987 394 786 408 328 531 540
preferredStock 4M 4M 4M 4M 4M 4M 4M
commonStock 225.000 225.000 166.000 1665.000 1664.000 1664.000 1664.000
retainedEarnings -48M -47M -46M -45M -43M -42M -40M
accumulatedOtherComprehensiveIncomeLoss -225.000 -225.000 -166.000 0 0 0 0
othertotalStockholdersEquity 49M 49M 46M 45M 45M 45M 44M
totalStockholdersEquity 4M 5M 3M 4M 5M 6M 7M
totalEquity 4M 5M 3M 4M 5M 6M 7M
totalLiabilitiesAndStockholdersEquity 4M 5M 3M 4M 6M 7M 8M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 4M 5M 3M 4M 6M 7M 8M
totalInvestments 0 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0
netDebt -4M -5M -3M -4M -5M -7M -8M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol LIXT LIXT LIXT LIXT LIXT LIXT LIXT
reportedCurrency USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-19 2023-11-09 2023-08-09 2023-05-10 2023-03-29 2022-11-08 2022-08-10
acceptedDate 2024-03-19 08:30:54 2023-11-09 17:16:22 2023-08-09 08:30:41 2023-05-10 08:30:30 2023-03-29 08:30:42 2022-11-08 08:30:31 2022-08-10 08:30:52
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -1M -1M -2M -1M -2M -1M -2M
depreciationAndAmortization 0 0 0 0 0 0 0
deferredIncomeTax 0 0 0 0 0 0 0
stockBasedCompensation 104 057 112 106 280 060 276 980 385 391 396 883 424 094
changeInWorkingCapital 26 075 -37 735 212 911 -180 690 37 465 -92 806 -72 050
accountsReceivables 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0
accountsPayables -65 383 -145 357 142 897 -6133.000 -77 634 81 433 0
otherWorkingCapital 91 458 107 622 70 014 -174 557 115 099 -174 239 -116 271
otherNonCashItems -1.000 257 463 0 0 0 0 0
netCashProvidedByOperatingActivities -902 123 -944 389 -1M -1M -1M -1M -1M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 -5M 5M 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 -5M 5M 0
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 0 3M 0 0 -5M 0 5M
commonStockRepurchased 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 0 41.000 0 6281.000 5M 5M 10 906
netCashUsedProvidedByFinancingActivities 0 3M 0 6281.000 5M 5M 5M
effectOfForexChangesOnCash 0 0 0 0 0 0 0
netChangeInCash -902 123 2M -1M -1M -1M -1M 4M
cashAtEndOfPeriod 4M 5M 3M 4M 5M 7M 8M
cashAtBeginningOfPeriod 5M 3M 4M 5M 7M 8M 4M
operatingCashFlow -902 123 -944 389 -1M -1M -1M -1M -1M
capitalExpenditure 0 0 0 0 0 0 0
freeCashFlow -902 123 -944 389 -1M -1M -1M -1M -1M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-01-29 13:30 ET
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
2023-11-13 13:30 ET
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
2023-10-16 12:30 ET
LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
2023-10-09 12:30 ET
LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
2023-09-26 12:30 ET
LIXTE Appoints Bas van der Baan as President and Chief Executive Officer
2023-09-20 12:30 ET
LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
2023-07-18 12:00 ET
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
2023-07-17 12:30 ET
Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
2023-06-23 12:30 ET
LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
2023-06-07 12:30 ET
LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
2023-06-02 16:30 ET
LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023
2023-05-30 12:30 ET
Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy
2023-04-24 12:30 ET
LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma
2023-04-04 12:30 ET
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer
2023-02-14 18:50 ET
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
2023-02-07 17:16 ET
LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
2022-11-30 13:05 ET
LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference
2022-10-13 12:30 ET
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
2022-06-21 12:30 ET
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS
2022-06-15 12:30 ET
LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS
2022-04-14 18:54 ET
WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering
2022-04-13 13:00 ET
WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
2022-04-13 12:30 ET
WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)
2022-04-12 17:52 ET
LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market
2022-04-12 12:30 ET
LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations
2022-03-22 12:30 ET
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
2022-03-16 12:30 ET
LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference
2022-01-12 13:30 ET
Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100
2022-01-05 13:30 ET
Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
2021-11-22 14:25 ET
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
2021-10-20 13:25 ET
Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
2021-10-13 13:25 ET
Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment
2021-08-17 13:25 ET
Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction
2021-08-03 13:25 ET
LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY
2021-07-22 13:25 ET
LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
2021-07-13 13:25 ET
Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer
2021-07-07 13:35 ET
Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021
2021-06-02 13:35 ET
Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer
2021-05-12 13:35 ET
LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS
2021-05-04 20:30 ET
Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20
2021-04-28 13:35 ET
Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14
2021-04-13 13:35 ET
Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors
2021-03-17 13:35 ET
Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
2021-03-03 14:35 ET
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
2021-03-02 23:38 ET
WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
2021-03-02 20:41 ET
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.
2021-03-02 15:30 ET
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
2021-03-01 13:45 ET
Lixte Biotechnology Announces $4.19 Million Registered Direct Offering
2021-02-24 14:35 ET
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
2021-01-19 14:35 ET
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer
2020-12-01 20:28 ET
WallachBeth Capital Announces Completion of $5.7 Million Joint Underwritten Public Offering for Lixte Biotechnology Holdings, Inc.
2020-12-01 17:30 ET
Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq
2020-11-30 20:52 ET
WestPark Capital Announces Closing of $5,700,000 Follow-On Offering and NASDAQ Up-listing of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT, LIXTW)
2020-11-25 13:30 ET
Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
2020-08-18 13:35 ET
The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
2020-07-21 13:35 ET
Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
2020-04-30 14:30 ET
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
2019-12-04 14:35 ET
First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology’s LB-100 to Enter Recurrent Malignant Brain Tumors

SEC forms

Show financial reports only

SEC form 10
2024-03-19 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q4
SEC form 10
2023-11-09 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q3
SEC form 10
2023-08-09 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q2
SEC form 6
2023-07-21 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q2
SEC form 6
2023-07-20 11:45 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q2
SEC form 6
2023-06-26 06:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 10
2023-05-10 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2023 q1
SEC form 6
2023-05-09 18:57 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 6
2023-04-25 15:48 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 6
2023-04-11 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 6
2023-04-05 09:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2023 q1
SEC form 10
2023-03-29 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q4
SEC form 10
2023-03-29 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q4
SEC form 6
2023-03-24 17:14 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q4
SEC form 6
2023-02-15 15:50 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q4
SEC form 6
2023-02-09 21:21 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q4
SEC form 6
2022-12-23 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-12-06 17:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-12-02 16:31 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-11-10 16:10 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 10
2022-11-08 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q3
SEC form 6
2022-10-18 13:14 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-10-11 06:15 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q3
SEC form 6
2022-08-26 14:48 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q2
SEC form 6
2022-08-15 18:34 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q2
SEC form 10
2022-08-10 08:30 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q2
SEC form 6
2022-06-24 17:10 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-06-23 08:09 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-06-16 18:47 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-05-13 13:40 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 10
2022-05-11 08:15 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Lixte Biotechnology Holdings, Inc. reported for 2022 q1
SEC form 6
2022-04-14 20:20 ET
Lixte Biotechnology Holdings, Inc. published news for 2022 q1
SEC form 6
2022-03-23 12:54 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q4
SEC form 10
2022-03-21 08:01 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q4
SEC form 10
2022-03-21 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q4
SEC form 10
2021-11-10 08:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q3
SEC form 6
2021-10-13 10:01 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q3
SEC form 6
2021-09-20 17:21 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 10
2021-08-10 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 6
2021-07-09 17:30 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q2
SEC form 6
2021-06-03 15:21 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-05-24 19:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-05-14 14:42 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-05-13 14:12 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 10
2021-05-12 09:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 10
2021-05-12 00:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 6
2021-04-13 16:52 ET
Lixte Biotechnology Holdings, Inc. published news for 2021 q1
SEC form 10
2021-03-26 08:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q4
SEC form 6
2021-03-02 16:55 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q4
SEC form 6
2021-01-22 14:00 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q4
SEC form 6
2020-12-01 20:51 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q3
SEC form 6
2020-11-27 16:43 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q3
SEC form 10
2020-11-10 16:05 ET
Lixte Biotechnology Holdings, Inc. published news for 2020 q3